Doxorubicin News and Research

RSS

Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.

Mitochondrial stress triggers long-term protection against heart damage

Mitochondria are popularly known as the "powerhouse of the cell," but these cellular structures do so much more-including acting as signaling hubs.

4 Sep 2026

Scientists uncover safer way to tame cancer cell senescence

Stopping tumor growth is only half the battle. Rather than kill tumor cells, many cancer therapies can only push them into cellular senescence, a state in which cells stop dividing but do not die. These "undead" cells will continue to release signals that reshape the tumor environment.

20 Aug 2026

Dual immunotherapy with neoadjuvant chemotherapy shows encouraging activity in ERBB2-negative breast cancer

A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given prior to surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to phase 2 clinical trial results from the ongoing I-SPY2 clinical trial platform.

30 Jul 2026

Brain cancer Achilles heel revealed in the hours after surgery

Scientists in Britain and Spain have discovered critical windows after glioblastoma surgery when the brain’s defenses falter, creating a rare chance to deliver powerful treatments exactly where needed.

29 Jul 2026

Phase 3 clinical trial enrolls first platinum-resistant ovarian cancer patient

The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3132/BEHOLD-Ovarian01 (NCT07286266), a global Phase 3 clinical trial titled A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants with Platinum-resistant Ovarian Cancer.

27 Jul 2026

Study reveals how specific aging cells help repair injured tendons

Tendon injuries, though very common, frequently heal with scar tissue, which is less flexible and more prone to future injury.

3 Jul 2026

Tiny algae-based robots could improve bladder cancer treatment

Tiny algae-based robots guided by magnets could improve bladder cancer treatment by boosting delivery of chemotherapy drugs into tumours, researchers say.

22 Jun 2026

Light-driven nanomotors improve multimodal breast cancer treatment efficacy

The nanomotor starts with bowl‑shaped mesoporous polydopamine (PDA) nanoparticles. These biocompatible bowls are loaded with two key payloads: Fe(II) ions as a Fenton catalyst, and BNN6, a thermally sensitive NO donor.

21 May 2026

Study explains how APOE2 gene protects the brain against Alzheimer's disease

People who carry the APOE2 version of the apolipoprotein E gene are more likely to live to advanced age and are partly protected against Alzheimer's disease, but scientists have struggled to explain why.

13 May 2026

New nanoparticles disable drug resistance to achieve complete tumor elimination

Cancer cells frequently develop the ability to expel anticancer drugs before they can work -- a phenomenon called multidrug resistance (MDR) -- which is one of the leading reasons why chemotherapy fails in patients.

8 May 2026

Experimental drug kills aggressive breast cancer by toxic fat buildup

An experimental drug targeting triple-negative breast cancer overwhelms cancer cells with toxic fats, according to new tests on human-derived tumors in mice.

22 Apr 2026

Targeted therapy treats mixed histiocytosis following multiple skull relapses

Mixed histiocytosis (Langerhans cell histiocytosis [LCH] / Erdheim-Chester disease [ECD]) developing after treatment for initial skull LCH is not well recognized.

13 Apr 2026

Precision medicine tools offer hope for patients with rare blood cancers

Personalized approaches have dramatically improved outcomes for many patients with non-Hodgkin B-cell lymphomas—blood cancers that arise in immune cells called B cells—yet the same is not true for patients with more rare lymphoma types that originate in immune cells called T cells.

9 Apr 2026

Early blood test could guide personalized lymphoma treatment decisions

Many people with an aggressive blood cancer called diffuse large B cell lymphoma are cured by the current gold standard of treatment: an antibody designed to wipe out cancerous B cells plus a combination of four chemotherapy drugs.

25 Mar 2026

Repurposed cancer drug shows promise against drug-resistant herpes infections

UIC researchers have successfully repurposed an FDA-approved cancer drug, doxorubicin, to treat drug-resistant strains of herpes. Their work appears in the journal Drug Resistance Updates.

24 Mar 2026

Researchers achieve breakthrough in the production of vital chemotherapy agent

An international team of researchers has achieved a breakthrough in the production of doxorubicin, a vital chemotherapy agent.

13 Mar 2026

New strategy boosts immunotherapy against aggressive ovarian cancer

Cells in our immune system are best known for providing security against external invaders such as bacteria and viruses. These immune cells also guard against internal threats, including cancerous tumors.

5 Mar 2026

Blocking growth hormone receptor may improve treatment response in lung cancer

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

2 Mar 2026

Frog-derived bacteria offer dual-action anticancer effects and high safety

A research team of Prof. Eijiro Miyako at the Japan Advanced Institute of Science and Technology (JAIST) has discovered that the bacterium Ewingella americana, isolated from the intestines of Japanese tree frogs (Dryophytes japonicus), possesses remarkably potent anticancer activity. This groundbreaking research has been published in the international journal Gut Microbes.

16 Dec 2025

Preoperative radiation may enhance treatment response in patients with HR-positive, HER2-negative breast cancer

Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative breast cancer when administered in combination with pembrolizumab (Keytruda) and chemotherapy and led to improved treatment responses prior to surgery, according to the results of the phase II P-RAD clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

11 Dec 2025